Open Surgery Offers Better Survival Chances than Minimally Invasive Surgery for Cervical Cancer
Posted on 22 Mar 2022
Minimally invasive surgery (MIS) was associated with lower survival rates than open surgery as a treatment for cervical cancer, according to the final analysis of data from the Laparoscopic Approach to Cervical Cancer (LACC) trial.
The Phase 3 LACC trial by researchers at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) compared long-term outcomes after laparoscopic or robot-assisted radical hysterectomy (MIS) with outcomes after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer. The trial enrolled a total of 631 patients, 319 of whom were assigned to MIS and 312 to open surgery, with a primary outcome measure of disease-free survival at 4.5 years.
A final analysis of data from the trial found the rate of disease-free survival was lower for MIS than open surgery: 43 MIS patients (13.5%) had disease at 4.5 years compared with 11 open surgery patients (3.5%). It also demonstrated that the MIS approach was associated with four times higher recurrence rates compared with the open approach. A previously published study, based on an interim analysis of survival rates (59.7% of patients followed to 4.5 years) of the LACC trial patients, reported similar results.
“Radical hysterectomy remains the standard recommendation for patients with early-stage cervical cancer, and there have been no prospective data on outcomes for minimally invasive surgery – until the LACC trial,” said principal investigator Pedro Ramirez, MD, professor of gynecologic oncology & reproductive medicine at The University of Texas MD Anderson Cancer Center, who was also first author on the previous study. “This final analysis of results from the LACC trial demonstrates that, despite being more invasive, open surgery offers these patients a lower recurrence rate and a better chance of disease-free survival than minimally invasive surgical approaches.”
Subgroup analyses of the final data also showed that the poorer disease-free survival for MIS patients was associated with larger tumor size (≥ 2 cm), and rates of carcinomatosis (tumor spreading) at disease recurrence was higher for MIS patients (25%) than for open surgery patients (0%).
“Our results from this subgroup analysis suggest that the likely reason for worse outcomes in patients who undergo MIS is tumor spillage or contamination, as worse outcomes are accentuated in patients with larger tumors and the rates of carcinomatosis are significantly higher in the MIS group,” added Ramirez.
Related Links:
University of Texas MD Anderson Cancer Center
